Advertisement

Vasculitis and Ulceration

  • Pinjala Ramakrishna
Chapter

Abstract

Vasculitis accounts for the presence of lower-extremity ulcers in 20 % of the patients. Inflammation associated with vasculitis compromises or destroys the vessel wall leading to local hemorrhagic or ischemic events. Skin biopsies are gold standard for the diagnosis of cutaneous vasculitis. The morphology depends on the size of the vessel and extent of the vascular bed affected. The treatment depends on the type, nature, and severity of the vasculitis. These ulcers are resistant to conventional therapies. Immune modulation therapy plays an important role along with the standard wound care measures in healing the ulcers.

Keywords

Giant Cell Arteritis Hemorrhagic Cystitis Cutaneous Vasculitis Palpable Purpura Cryoglobulinemic Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Herber OR, Schnepp W, Rieger MA. A systematic review on the impact of leg ulceration on patients’ quality of life. Health Qual Life Outcomes. 2007;5:44.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Carlson JA, Ng BT, Chen KR. Cutaneous vasculitis update: diagnostic criteria, classification, epidemiology, etiology, pathogenesis, evaluation and prognosis. Am J Dermatopathol. 2005;27:504–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Thurtle OA, Cawley MI. The frequency of leg ulceration in rheumatoid arthritis: a survey. J Rheumatol. 1983;10(3):507–9.PubMedGoogle Scholar
  4. 4.
    Chen KR, Toyohara A, Suzuki A, Miyakawa S. Clinical and histopathological spectrum of cutaneous vasculitis in rheumatoid arthritis. Br J Dermatol. 2002;147:905–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Mongan ES, Cass RM, Jacox RF, Vaughen JH. A study of the relation of seronegative and seropositive rheumatoid arthritis to each other and to necrotizing vasculitis. Am J Med. 1969;47(1):23–35.CrossRefPubMedGoogle Scholar
  6. 6.
    Fries JF, Hunder GG, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum. 1990;33:1135–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140(1):131–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Suresh E. Diagnostic approach to patients with suspected vasculitis. Postgrad Med J. 2006;82:483–8.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen KR. Cutaneous polyarteritis nodosa: a clinical and histopathological study of 20 cases. J Dermatol. 1989;16(6):429–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Milstone LM, Braverman IM, Lucky P, Fleckman P. Classification and therapy of atrophie blanche. Arch Dermatol. 1983;119(12):963–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Jetton RL, Lazarus GS. Minidose heparin therapy for vasculitis of atrophie blanche. J Am Acad Dermatol. 1983;8(1):23–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Della Bella S, Molteni M, Mocellin C, et al. Novel mode of action of iloprost: in vitro down-regulation of endothelial cell adhesion molecules. Prostaglandins Other Lipid Mediat. 2001;65:73–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Scott DG, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med. 1984;76(3):377–84.CrossRefPubMedGoogle Scholar
  14. 14.
    Lapraik C, Watts R, Scott DG. Modern management of primary systemic vasculitis. Clin Med. 2007;7(1):43–7.CrossRefGoogle Scholar
  15. 15.
    Takeuchi A, Hashimoto T. Oral prostaglandin E1 as a therapeutic modality for leg ulcers in Behcet’s disease. Int J Clin Pharmacol Res. 1987;7(4):283–9.PubMedGoogle Scholar

Copyright information

© Springer India 2016

Authors and Affiliations

  1. 1.Department of Vascular SurgeryNizam’s Institute of Medical SciencesHyderabadIndia

Personalised recommendations